| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 27 | 2022 | 778 | 3.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 6 | 2022 | 32 | 2.470 |
Why?
|
| Circulating Tumor DNA | 4 | 2022 | 7 | 1.930 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 17 | 2010 | 87 | 1.390 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2015 | 331 | 1.280 |
Why?
|
| Antineoplastic Agents | 14 | 2016 | 1070 | 1.140 |
Why?
|
| Receptors, Androgen | 5 | 2022 | 33 | 1.050 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2010 | 411 | 0.970 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 17 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 467 | 0.760 |
Why?
|
| Biomarkers, Tumor | 9 | 2020 | 508 | 0.730 |
Why?
|
| Mutation | 6 | 2020 | 1213 | 0.690 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 334 | 0.640 |
Why?
|
| Antibodies, Bispecific | 1 | 2017 | 11 | 0.630 |
Why?
|
| Pyrimidines | 3 | 2013 | 178 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 756 | 0.590 |
Why?
|
| Apoptosis | 13 | 2015 | 1640 | 0.590 |
Why?
|
| Thiazoles | 2 | 2013 | 95 | 0.540 |
Why?
|
| Prostate-Specific Antigen | 8 | 2022 | 138 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 444 | 0.510 |
Why?
|
| Taxoids | 3 | 2011 | 41 | 0.510 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 307 | 0.470 |
Why?
|
| Orchiectomy | 1 | 2013 | 25 | 0.470 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 70 | 0.460 |
Why?
|
| Cell Line, Tumor | 15 | 2018 | 1849 | 0.450 |
Why?
|
| Male | 41 | 2022 | 37281 | 0.450 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2015 | 32 | 0.430 |
Why?
|
| Humans | 69 | 2022 | 68525 | 0.430 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2011 | 73 | 0.420 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 11 | 0.400 |
Why?
|
| Boronic Acids | 1 | 2011 | 40 | 0.400 |
Why?
|
| Pyrazines | 1 | 2011 | 46 | 0.400 |
Why?
|
| Mice | 30 | 2022 | 8472 | 0.380 |
Why?
|
| Melanoma | 3 | 2022 | 335 | 0.380 |
Why?
|
| Salvage Therapy | 1 | 2010 | 82 | 0.350 |
Why?
|
| Tumor Cells, Cultured | 10 | 2012 | 852 | 0.350 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 475 | 0.350 |
Why?
|
| Animals | 36 | 2022 | 20877 | 0.330 |
Why?
|
| Carrier Proteins | 4 | 2011 | 597 | 0.330 |
Why?
|
| Cell Survival | 8 | 2009 | 901 | 0.330 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 2550 | 0.320 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2009 | 282 | 0.310 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2001 | 17 | 0.310 |
Why?
|
| Lactones | 4 | 1995 | 64 | 0.310 |
Why?
|
| Aged | 16 | 2022 | 14842 | 0.300 |
Why?
|
| Chromones | 1 | 2007 | 33 | 0.300 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2001 | 195 | 0.300 |
Why?
|
| Flurbiprofen | 1 | 2006 | 3 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 331 | 0.290 |
Why?
|
| Signal Transduction | 12 | 2018 | 2688 | 0.280 |
Why?
|
| Milk Proteins | 3 | 2001 | 22 | 0.280 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 370 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 332 | 0.280 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 349 | 0.270 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4843 | 0.260 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2003 | 268 | 0.260 |
Why?
|
| Genes, p53 | 1 | 2005 | 41 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2007 | 498 | 0.260 |
Why?
|
| Phosphorylation | 11 | 2010 | 1199 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2007 | 376 | 0.250 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 1998 | 101 | 0.250 |
Why?
|
| Diphtheria Toxin | 2 | 2002 | 18 | 0.250 |
Why?
|
| Growth Substances | 2 | 1999 | 77 | 0.250 |
Why?
|
| RNA, Messenger | 11 | 2010 | 1663 | 0.240 |
Why?
|
| Middle Aged | 14 | 2022 | 21119 | 0.240 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2005 | 138 | 0.240 |
Why?
|
| Vaccinia virus | 1 | 2005 | 97 | 0.240 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2015 | 9 | 0.230 |
Why?
|
| Neoplasms | 4 | 2020 | 1660 | 0.230 |
Why?
|
| Serine | 1 | 2003 | 99 | 0.230 |
Why?
|
| Androgen Antagonists | 2 | 2015 | 44 | 0.230 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 799 | 0.230 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 42 | 0.230 |
Why?
|
| Cellular Senescence | 2 | 2016 | 112 | 0.230 |
Why?
|
| Genetic Therapy | 1 | 2005 | 291 | 0.220 |
Why?
|
| Cell Proliferation | 9 | 2016 | 1173 | 0.220 |
Why?
|
| Protein Binding | 5 | 2020 | 1027 | 0.220 |
Why?
|
| BRCA1 Protein | 2 | 2020 | 30 | 0.220 |
Why?
|
| Down-Regulation | 4 | 2012 | 447 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7264 | 0.220 |
Why?
|
| Inflammasomes | 1 | 2022 | 39 | 0.220 |
Why?
|
| Interleukin-3 | 6 | 2004 | 63 | 0.210 |
Why?
|
| Cryptococcus | 1 | 2022 | 7 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 78 | 0.210 |
Why?
|
| Dasatinib | 2 | 2013 | 17 | 0.210 |
Why?
|
| Immunotoxins | 1 | 2002 | 23 | 0.210 |
Why?
|
| Prostatectomy | 3 | 2021 | 87 | 0.210 |
Why?
|
| Proteolysis | 2 | 2020 | 97 | 0.210 |
Why?
|
| Transfection | 10 | 2015 | 782 | 0.210 |
Why?
|
| NF-kappa B | 2 | 2018 | 432 | 0.210 |
Why?
|
| Carcinogenesis | 3 | 2020 | 124 | 0.210 |
Why?
|
| Patient Portals | 1 | 2021 | 12 | 0.200 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 49 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.200 |
Why?
|
| Trans-Activators | 3 | 2001 | 237 | 0.200 |
Why?
|
| Cell Line | 10 | 2011 | 1752 | 0.190 |
Why?
|
| Cell Nucleus | 4 | 2017 | 305 | 0.190 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 12 | 0.190 |
Why?
|
| Leukemia | 3 | 2010 | 117 | 0.190 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 18 | 0.190 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2020 | 14 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 19 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 51 | 0.180 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2010 | 37 | 0.180 |
Why?
|
| Thrombin | 1 | 2020 | 117 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2015 | 510 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 27 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 174 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 2093 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.170 |
Why?
|
| Disease Progression | 4 | 2021 | 1037 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 99 | 0.160 |
Why?
|
| Protein Kinases | 2 | 2009 | 122 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 168 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2001 | 700 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2010 | 231 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 142 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 146 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2018 | 125 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 306 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2017 | 235 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 114 | 0.150 |
Why?
|
| Interleukin-6 | 2 | 2017 | 330 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Flavonoids | 3 | 2007 | 109 | 0.150 |
Why?
|
| Time Factors | 9 | 2021 | 4655 | 0.150 |
Why?
|
| Cytokines | 3 | 2018 | 866 | 0.150 |
Why?
|
| Cell Cycle | 4 | 2009 | 312 | 0.150 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 9 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.150 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 21 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 1998 | 5 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2020 | 617 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2012 | 118 | 0.140 |
Why?
|
| Exosomes | 2 | 2016 | 44 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2016 | 113 | 0.140 |
Why?
|
| Chalcone | 1 | 2015 | 1 | 0.140 |
Why?
|
| Burkitt Lymphoma | 2 | 2008 | 18 | 0.140 |
Why?
|
| Ubiquitins | 1 | 2015 | 22 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 1 | 2015 | 52 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.130 |
Why?
|
| RNA, Neoplasm | 3 | 2010 | 76 | 0.130 |
Why?
|
| Phenotype | 4 | 2016 | 946 | 0.130 |
Why?
|
| Adamantane | 1 | 2015 | 40 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 28 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2015 | 117 | 0.130 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.130 |
Why?
|
| Ellagic Acid | 1 | 2014 | 1 | 0.130 |
Why?
|
| Linolenic Acids | 1 | 2014 | 3 | 0.130 |
Why?
|
| Luteolin | 1 | 2014 | 3 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 659 | 0.130 |
Why?
|
| Mitochondria | 1 | 1999 | 643 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 5 | 2020 | 532 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 657 | 0.120 |
Why?
|
| Nomograms | 1 | 2014 | 19 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2015 | 200 | 0.120 |
Why?
|
| Transgenes | 3 | 2017 | 92 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 129 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2015 | 1745 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 304 | 0.120 |
Why?
|
| Pyridines | 1 | 2015 | 261 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 284 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 2 | 2017 | 86 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 110 | 0.120 |
Why?
|
| Testosterone | 1 | 2013 | 96 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 567 | 0.110 |
Why?
|
| Leukemia, Myeloid | 2 | 2007 | 39 | 0.110 |
Why?
|
| Benzoxazoles | 1 | 2012 | 12 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 40 | 0.110 |
Why?
|
| Mice, SCID | 4 | 2016 | 238 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2010 | 954 | 0.110 |
Why?
|
| Homes for the Aged | 1 | 2012 | 16 | 0.110 |
Why?
|
| Kava | 1 | 2012 | 1 | 0.110 |
Why?
|
| Prostate | 3 | 2020 | 116 | 0.110 |
Why?
|
| Nursing Homes | 1 | 2012 | 54 | 0.110 |
Why?
|
| Cell Division | 6 | 1997 | 541 | 0.110 |
Why?
|
| Kinetics | 4 | 2004 | 1047 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2018 | 7028 | 0.110 |
Why?
|
| Flow Cytometry | 6 | 2012 | 489 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 93 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2012 | 132 | 0.100 |
Why?
|
| Cell Cycle Proteins | 3 | 2010 | 230 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.100 |
Why?
|
| Cell Differentiation | 6 | 2009 | 1034 | 0.100 |
Why?
|
| Patient Transfer | 1 | 2012 | 86 | 0.100 |
Why?
|
| Molecular Weight | 3 | 1999 | 358 | 0.100 |
Why?
|
| Bortezomib | 1 | 2011 | 45 | 0.100 |
Why?
|
| Carotenoids | 1 | 2011 | 45 | 0.100 |
Why?
|
| bcl-Associated Death Protein | 3 | 2009 | 19 | 0.100 |
Why?
|
| Female | 10 | 2019 | 38015 | 0.100 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 34 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 235 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 365 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2009 | 202 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 63 | 0.090 |
Why?
|
| Inflammation | 1 | 2017 | 1030 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 26 | 0.090 |
Why?
|
| HeLa Cells | 3 | 2010 | 237 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 506 | 0.090 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 311 | 0.090 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2007 | 67 | 0.090 |
Why?
|
| Kallikreins | 2 | 2021 | 323 | 0.090 |
Why?
|
| Blotting, Northern | 3 | 2003 | 189 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2010 | 91 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 68 | 0.090 |
Why?
|
| Benzylidene Compounds | 1 | 2009 | 16 | 0.090 |
Why?
|
| Pleural Effusion | 1 | 2010 | 74 | 0.090 |
Why?
|
| Sarcoma | 1 | 2009 | 70 | 0.090 |
Why?
|
| Adipocytes | 1 | 2009 | 88 | 0.090 |
Why?
|
| Caspases | 1 | 2009 | 194 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 76 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 945 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1533 | 0.080 |
Why?
|
| Lysosomes | 1 | 2009 | 136 | 0.080 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 29 | 0.080 |
Why?
|
| Caregivers | 1 | 2012 | 365 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2009 | 791 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 304 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 206 | 0.080 |
Why?
|
| Sphingolipids | 1 | 2011 | 337 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 250 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2007 | 100 | 0.080 |
Why?
|
| Disease Management | 1 | 2010 | 248 | 0.080 |
Why?
|
| Mice, Nude | 4 | 2011 | 294 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2012 | 246 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mos | 1 | 2007 | 1 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 2356 | 0.080 |
Why?
|
| Bryostatins | 4 | 1995 | 32 | 0.080 |
Why?
|
| Nitriles | 2 | 2020 | 68 | 0.080 |
Why?
|
| Colony-Stimulating Factors | 1 | 1987 | 19 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 236 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2007 | 31 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 185 | 0.080 |
Why?
|
| Macrolides | 4 | 1995 | 48 | 0.080 |
Why?
|
| Indazoles | 1 | 2007 | 12 | 0.080 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2007 | 16 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 222 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2012 | 1329 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 1032 | 0.080 |
Why?
|
| Immunoglobulin Fragments | 1 | 2007 | 14 | 0.080 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2007 | 38 | 0.070 |
Why?
|
| Flavones | 1 | 2007 | 11 | 0.070 |
Why?
|
| Cancer Survivors | 2 | 2020 | 145 | 0.070 |
Why?
|
| Models, Biological | 2 | 2008 | 981 | 0.070 |
Why?
|
| Melanoma, Experimental | 1 | 1988 | 95 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 211 | 0.070 |
Why?
|
| GPI-Linked Proteins | 1 | 2006 | 27 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2010 | 682 | 0.070 |
Why?
|
| Drug Design | 1 | 2007 | 107 | 0.070 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 136 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2007 | 234 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 181 | 0.070 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 190 | 0.070 |
Why?
|
| Plasmids | 2 | 2005 | 258 | 0.070 |
Why?
|
| STAT5 Transcription Factor | 3 | 2001 | 18 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 711 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2009 | 214 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 562 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 2790 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 132 | 0.070 |
Why?
|
| Glutathione Transferase | 2 | 2004 | 166 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 1425 | 0.070 |
Why?
|
| Genes, Dominant | 2 | 2010 | 51 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2010 | 230 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2010 | 753 | 0.070 |
Why?
|
| Protein Subunits | 2 | 2007 | 99 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 5719 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2004 | 14 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 138 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 614 | 0.060 |
Why?
|
| Neoplasm Transplantation | 3 | 2012 | 160 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 322 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2003 | 50 | 0.060 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 32 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2003 | 59 | 0.060 |
Why?
|
| Janus Kinase 2 | 2 | 2001 | 40 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2003 | 65 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2003 | 251 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 1987 | 375 | 0.060 |
Why?
|
| Ubiquitination | 2 | 2015 | 85 | 0.060 |
Why?
|
| Recombinant Proteins | 4 | 1998 | 742 | 0.060 |
Why?
|
| Adult | 5 | 2020 | 21375 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2001 | 420 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2010 | 434 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 78 | 0.050 |
Why?
|
| Interleukin-8 | 2 | 2010 | 71 | 0.050 |
Why?
|
| United States | 3 | 2020 | 7335 | 0.050 |
Why?
|
| California | 1 | 2021 | 99 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 167 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 10 | 0.050 |
Why?
|
| B7-2 Antigen | 1 | 2001 | 23 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2001 | 81 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 271 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2022 | 239 | 0.050 |
Why?
|
| Microbiota | 1 | 2022 | 79 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2010 | 1692 | 0.050 |
Why?
|
| Androstenes | 1 | 2020 | 6 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2020 | 71 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 131 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2010 | 53 | 0.050 |
Why?
|
| Germ Cells | 1 | 2020 | 17 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1991 | 30 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 122 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2010 | 254 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 111 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 1999 | 89 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2010 | 2673 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 307 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5708 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
| Adolescent | 2 | 2010 | 8903 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 523 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 84 | 0.040 |
Why?
|
| Head Injuries, Closed | 1 | 1997 | 9 | 0.040 |
Why?
|
| Concept Formation | 1 | 1997 | 16 | 0.040 |
Why?
|
| Problem Solving | 1 | 1997 | 36 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 2264 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| COS Cells | 2 | 2010 | 155 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 848 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2018 | 156 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1174 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 1989 | 116 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1991 | 626 | 0.040 |
Why?
|
| Child Development | 1 | 1997 | 102 | 0.040 |
Why?
|
| Sirolimus | 2 | 2010 | 118 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1997 | 62 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 1998 | 56 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 42 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2016 | 147 | 0.040 |
Why?
|
| Oncogenes | 1 | 2017 | 71 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 710 | 0.040 |
Why?
|
| Cell Communication | 1 | 2016 | 116 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 110 | 0.040 |
Why?
|
| NEDD8 Protein | 1 | 2015 | 2 | 0.030 |
Why?
|
| Monocytes | 2 | 1997 | 210 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Cullin Proteins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2016 | 3185 | 0.030 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1995 | 17 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 69 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2015 | 22 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 75 | 0.030 |
Why?
|
| Cyclins | 1 | 1995 | 50 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2017 | 221 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2015 | 6 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 78 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Anilides | 1 | 2015 | 16 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 2003 | 1446 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 517 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1995 | 138 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1995 | 60 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 97 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 1465 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1997 | 342 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 785 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 48 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1993 | 765 | 0.030 |
Why?
|
| Control Groups | 1 | 2014 | 10 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 151 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2004 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 88 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 216 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3256 | 0.030 |
Why?
|
| Biological Products | 1 | 2014 | 78 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 183 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 492 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 2012 | 7 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1548 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 78 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2013 | 174 | 0.030 |
Why?
|
| British Columbia | 1 | 2012 | 3 | 0.030 |
Why?
|
| Alberta | 1 | 2012 | 15 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2012 | 25 | 0.030 |
Why?
|
| Gene Expression | 2 | 1992 | 770 | 0.030 |
Why?
|
| Vanadates | 1 | 1992 | 12 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 371 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2012 | 45 | 0.030 |
Why?
|
| Protein Kinase C | 2 | 1994 | 270 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 785 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 2012 | 43 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2012 | 168 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2012 | 94 | 0.030 |
Why?
|
| Neutrophils | 1 | 1993 | 204 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 849 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2016 | 447 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 67 | 0.030 |
Why?
|
| Ceramides | 1 | 2015 | 578 | 0.030 |
Why?
|
| Binding Sites | 2 | 2007 | 631 | 0.030 |
Why?
|
| Medicare | 1 | 2013 | 316 | 0.030 |
Why?
|
| Focus Groups | 1 | 2012 | 247 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1992 | 217 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 144 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 139 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1419 | 0.020 |
Why?
|
| Peroxiredoxin III | 1 | 2010 | 1 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 209 | 0.020 |
Why?
|
| Lactoferrin | 1 | 1990 | 6 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 248 | 0.020 |
Why?
|
| Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2010 | 5 | 0.020 |
Why?
|
| S Phase | 1 | 2010 | 38 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Polyploidy | 1 | 2010 | 24 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1990 | 65 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2010 | 88 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 196 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 730 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 272 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2010 | 41 | 0.020 |
Why?
|
| Vacuoles | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 93 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 176 | 0.020 |
Why?
|
| Caspase 2 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2009 | 24 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2009 | 36 | 0.020 |
Why?
|
| K562 Cells | 1 | 2009 | 44 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 61 | 0.020 |
Why?
|
| Cathepsin B | 1 | 2009 | 33 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1992 | 384 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 320 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 65 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 93 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 37 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 233 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1293 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 75 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 1082 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 397 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 1988 | 33 | 0.020 |
Why?
|
| Leukocytosis | 1 | 1987 | 13 | 0.020 |
Why?
|
| Granulocytes | 1 | 1987 | 22 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1987 | 15 | 0.020 |
Why?
|
| Cytarabine | 1 | 2007 | 44 | 0.020 |
Why?
|
| Culture Media | 1 | 1988 | 155 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 439 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2007 | 6 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 7 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 169 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 260 | 0.020 |
Why?
|
| Static Electricity | 1 | 2007 | 91 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2007 | 74 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2007 | 231 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 317 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1139 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 658 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 22 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 648 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2005 | 17 | 0.020 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2005 | 11 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1997 | 155 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 902 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 67 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2007 | 546 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2007 | 267 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 90 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2004 | 21 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2004 | 37 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 100 | 0.020 |
Why?
|
| Furans | 1 | 2004 | 27 | 0.020 |
Why?
|
| Carbazoles | 1 | 2004 | 46 | 0.020 |
Why?
|
| RNA Interference | 1 | 2005 | 266 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 299 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2007 | 621 | 0.020 |
Why?
|
| Indoles | 1 | 2004 | 146 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 171 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 705 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2003 | 24 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 1015 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 88 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 258 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1998 | 8 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1998 | 37 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1998 | 19 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1998 | 41 | 0.010 |
Why?
|
| Point Mutation | 1 | 1998 | 97 | 0.010 |
Why?
|
| Volition | 1 | 1997 | 16 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 1997 | 65 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 329 | 0.010 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1997 | 15 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1997 | 26 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1997 | 60 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 107 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 290 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1995 | 33 | 0.010 |
Why?
|
| Attention | 1 | 1997 | 225 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 1046 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 35 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 122 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1054 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1994 | 204 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 357 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 473 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1993 | 74 | 0.010 |
Why?
|
| Genes, abl | 1 | 1992 | 4 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1992 | 26 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1992 | 108 | 0.010 |
Why?
|
| Fibronectins | 1 | 1992 | 130 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1993 | 455 | 0.010 |
Why?
|
| Collagen | 1 | 1992 | 636 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 493 | 0.010 |
Why?
|
| Child | 1 | 1997 | 6400 | 0.000 |
Why?
|